IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Mayo Clinic
Study ID
NCT05372003
Phase
EARLY_PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Dupilumab — DRUG
    dupilumab injections will be prescribed and managed by dermatology as standard of care
  • Photo therapy — OTHER
    light therapy will be prescribed and managed by dermatology as standard of care

Study Details

The purpose of this study is to better understand the interactions between the innate immune system, in particular eosinophils, their secreted cytokines (interleukin-4), and metabolism in human health and disease states such as obesity and insulin resistance.

Key Dates

Start date
Aug 9, 2022
Status verified
Feb 2024
Primary completion
Feb 23, 2024
Completion
Feb 23, 2024

Study Design

Enrollment
7 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Subjects on Dupilumab
    individuals with atopic dermatitis placed on dupilumab for more than 6 months will be eligible to this study. Their metabolic profile will be compared to the group of "Subjects on Phototherapy"
  • Active Comparator: Subjects on Phototherapy
    individuals with atopic dermatitis placed on phototherapy for more than 6 months will be eligible to this study to serve as an active comparator to the "Subjects with Dupilumab"

Primary Outcome Measure

Homa IR [ Time Frame: baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic ArizonaScottsdaleArizona85259-

Find similar trials in Scottsdale, AZ

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Mayo Clinic Arizona· Scottsdale, AZ

Related Studies